FOR RESEARCH USE ONLY — All compounds sold for in vitro laboratory research  •  99%+ PURITY GUARANTEED  •  THIRD-PARTY HPLC & MASS SPECTROMETRY VERIFIED  •  COLD-CHAIN OPTIMISED SHIPPING  • 
Metabolic In Vitro Research Only

AOD-9604: GH Fragment Fat-Loss Research Without IGF-1 Elevation

GRAS FDA Generally Recognized As Safe Status

AOD-9604 (hGH[176–191]) is a synthetic C-terminal fragment of human Growth Hormone with a tyrosine N-terminus addition, developed by Metabolic Pharmaceuticals (Australia) and studied by Professor Norman Baxter at Monash University. It reached Phase IIb/III clinical trials for obesity. Its critical distinction: it replicates GH's lipolytic activity through a beta-3 adrenergic-like pathway while producing no IGF-1 elevation, no insulin resistance, and no anabolic effects — confirmed across multiple human studies.

For in vitro laboratory research use only. Not for human consumption. All findings described are from preclinical or in vitro models.

MECHANISMS OF ACTION

In vitro and preclinical mechanistic observations

🔥

Adipocyte Lipolysis Stimulation

Stimulates lipolysis in fat cells and inhibits lipogenesis through direct receptor interactions — independent of the GH receptor binding that causes full GH's systemic effects.

⚗️

Beta-3 Adrenergic-Like Pathway

Operates via a fat-oxidation pathway structurally independent from GH receptor activation, explaining why it lacks GH's diabetogenic, anabolic, and growth-promoting properties.

🛡️

Zero IGF-1 Elevation

Confirmed in multiple human studies — no anabolic IGF-1 elevation, eliminating the theoretical cancer-growth concern associated with full GH administration.

🦴

Cartilage Regeneration (Emerging)

Stimulates proteoglycan synthesis in human chondrocytes in vitro and improves histological cartilage scores in rat OA models — an unexpected secondary finding now under investigation.

KEY RESEARCH DATA

Quantitative findings from published preclinical research

🏛️
GRAS
FDA Safety Status
Generally Recognized As Safe
💊
Phase IIb
Human Clinical Trial
307 obese adults, 24 weeks
🔬
0
IGF-1 Elevation
Confirmed human studies (Ng 2000)
🇦🇺
Monash
University Research
Prof. Norman Baxter

AOD-9604 vs. Full hGH — Safety & Metabolic Profile Comparison

Fat Loss Activity
78
IGF-1 Elevation
0
Insulin Resistance
0
Bone Growth Risk
0
Tolerability
94

AOD-9604 values. Source: Heffernan et al. (2001) J Endocrinol; Ng et al. (2000) J Endocrinol.

PRECLINICAL SAFETY PROFILE

Observed tolerability data from in vitro and animal model research

94%

Tolerability

Low Severity
0%

Insulin Resistance

Low Severity
6%

Injection-Site Rxn

Low Severity

Safety data reflects preclinical observations only. Human clinical safety profiles may differ substantially. For in vitro laboratory research use only. Not for human consumption.

RESEARCH CITATIONS

Primary literature — links open PubMed or original journal source

Syntra Compound Library

View AOD-9604 specifications, batch data, and Certificate of Analysis in the Syntra research compound catalogue.

View AOD-9604 in the Syntra Compound Library →

For in vitro laboratory research use only. Not for human consumption.

← Back to Peptide Research Library
Spend $100.00 more for free shipping
$0 Free at $100
Top Compounds →